文献速递肿瘤 PET/CT

基线18F-FDG PET/CT多种代谢参数在接受铂类化疗的非小细胞肺癌患者中的预后价值

Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
PubMed 文献 · Clin Nucl Med · 2018-01-01

该前瞻性研究纳入60例拟接受铂类化疗的活检证实非小细胞肺癌患者,于基线行区域动态及全身静态18F-FDG PET/CT,评估多种代谢参数对总生存(OS)的预测价值。中位随访4.4个月,单因素分析显示原发肿瘤MTV、TLG及全身肿瘤病灶MTV、TLG与OS显著相关,多因素分析显示MTV为OS的独立预后标志物。

要点

  • 原发肿瘤MTV、TLG及全身肿瘤病灶MTV、TLG与OS显著相关。
  • 多因素分析显示MTV为OS的独立预后标志物。
  • SUVmax、平均SUV、肿瘤/本底比值及动态参数无预后价值。

核心结论

  • 基线原发肿瘤及全身肿瘤病灶的MTV和TLG是接受铂类化疗的NSCLC患者OS的可靠预后标志物。
  • 其他基线全身PET/CT参数(SUVmax、平均SUV、肿瘤/本底比值)及动态PET/CT参数(净流入速率常数、葡萄糖代谢率)在这些患者中无预后价值。

研究设计与样本

  • 前瞻性研究纳入60例活检证实NSCLC且拟接受铂类化疗的患者,其中51例男性、9例女性,平均年龄59.55±10.06岁。
  • 每例患者静脉注射0.21 mCi/kg(5.18-7.77 MBq/kg)的18F-FDG后行基线区域动态及全身静态PET/CT。
  • 评估动态PET/CT参数:30分钟和60分钟的净流入速率常数及葡萄糖代谢率。
  • 评估全身PET/CT参数:原发肿瘤的SUVmax、平均SUV、肿瘤/本底比值、MTV、TLG,以及全身肿瘤病灶的MTV和TLG。
  • 采用ROC曲线分析计算所有参数的最佳截断值,采用log-rank检验、Kaplan-Meier曲线及Cox比例风险模型进行生存分析。

主要发现

  • 中位随访时间为4.4个月(范围8天至15.9个月)。
  • 单因素分析中,原发肿瘤MTV(截断值120 cm³,HR 3.64,P=0.001)、原发肿瘤TLG(截断值800,HR 3.35,P=0.002)、全身肿瘤病灶MTV(截断值160 cm³,HR 2.51,P=0.019)及全身肿瘤病灶TLG(截断值1350,HR 2.69,P=0.008)与OS显著相关。
  • 多因素生存分析中,MTV为OS的独立预后标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to prospectively evaluate the role of various quantitative and semiquantitative metabolic parameters derived from dynamic and static baseline F-FDG PET/CT in prediction of overall survival (OS) in non-small cell lung cancer (NSCLC) patients who were planned to undergo platinum-based chemotherapy. METHODS: Sixty patients (51 male and 9 female patients) with biopsy-proven NSCLC and mean age 59.55 ± 10.06 years who were planned to undergo platinum-based chemotherapy were enrolled in the study. Each patient underwent a baseline regional dynamic and a static whole-body F-FDG PET/CT after injecting 0.21 mCi/kg (5.18-7.77 MBq/kg) of F-FDG intravenously. Two dynamic PET/CT parameters, that is, net influx rate constant and glucose metabolic rate at 30 and 60 minutes, were evaluated. In addition, whole-body PET/CT parameters, that is, SUVmax, average SUV, tumor-to-background ratio, metabolic tumor volume (MTV), total lesion glycolysis (TLG) of the primary tumor, and MTV and TLG of whole-body tumor lesions, were evaluated. Best possible cutoffs for all parameters were calculated using receiver operating characteristic curve analysis. Survival analysis was performed using log-rank test, Kaplan-Meier curves, and Cox proportional hazards model to determine the prognostic markers for OS. RESULTS: The median follow-up period was 4.4 months (range, 8 days to 15.9 months). In univariate analysis, the 4 static whole-body PET/CT parameters, that is, MTV, TLG, and MTV and TLG of whole-body tumor lesions, were found to be significantly associated with OS with cutoff values of 120, 800, 160, and 1350 cm and hazard ratios of 3.64 (P = 0.001), 3.35 (P = 0.002), 2.51 (P = 0.019), and 2.69 (P = 0.008), respectively. In multivariate survival analysis, MTV was found to be an independent prognostic marker for OS. CONCLUSIONS: Baseline MTV and TLG evaluated from primary tumor as well as the whole-body tumor lesions are reliable prognostic markers of OS in NSCLC patients undergoing platinum-based chemotherapy. However, other baseline whole-body PET/CT parameters (SUVmax, average SUV, and tumor-to-background ratio) and dynamic PET/CT parameters (net influx rate constant, glucose metabolic rate) have no prognostic value in these patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sharma A, Mohan A, Bhalla AS, et al. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Clin Nucl Med. 2018. PMID: 29112011. doi:10.1097/RLU.0000000000001886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。